Immune modulation of paraneoplastic neurologic disorders
References (38)
- et al.
Regression of small cell lung carcinomas in patients with paraneoplastic neuronal antibodies
Lancet
(1993) - et al.
Sensory neuronopathy and small cell lung cancer: antineuronal antibody that also reacts with the tumor
Am. J. Med.
(1986) Paraneoplastic syndromes
Curr. Neurol.
(1989)- et al.
Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome
Ann. Neurol.
(1991) - et al.
Encephalomyelitis with carcinoma
- et al.
Myoclonic encephalopathy of infants
Adv. Neurol.
(1986) - et al.
Response of the Lambert-Eaton myasthenic syndrome to treatment associated small-cell lung carcinoma
Neurology
(1990) - et al.
Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients
Medicine
(1992) - et al.
Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients
Neurology
(1992) - et al.
Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes
Neurology
(1990)
Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation
Neurology
(1994)
Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease
Neurology
(1992)
Subacute motor neuronopathy: a remote effect of lymphoma
Ann. Neurol.
(1979)
Guillain-Barré syndrome and Hodgkin's disease: Three cases with immunological studies
Ann. Neurol.
(1977)
Autoimmune thrombocytopenia and peripheral neuropathy heralding Hodgkin's disease
South. Med. J.
(1975)
Peripheral neuropathy of sensorimotor type associated with malignant disease
Brain
(1967)
Mixed carcinomatous neuropathy in patients with lung cancer and lymphoma
Acta Neurol. Scand.
(1983)
The carcinomatous neuromyopathy of oat cell lung cancer
Ann. Neurol.
(1980)
Paraneoplastic cerebellar degeneration: clinical-immunological correlations
Ann. Neurol.
(1988)
Cited by (16)
Paraneoplastic Neurological Syndromes And Onconeural Antibodies: Clinical And Immunological Aspects
2007, Advances in Clinical ChemistryCitation Excerpt :Cytokine production by the responding T cells can amplify the process by promoting blood–brain barrier permeability, upregulation of MHC class I expression, and recruitment of additional T cells [7, 19]. There are two approaches to treating PNS: eradicating the source of the antigen, that is, the tumor, through surgery, radiotherapy, or chemotherapy; and modulating the immune response such as by administering corticosteroids, intravenous immunoglobuline or azathioprine, or depleting IgG (plasma exchange) [219, 220]. The single most important factor in managing patients with PNS is identifying and treating the associated tumor as early as possible, but even with complete tumor remission, the PNS respond to varying degrees [12, 221].
Paraneoplastic Neurologic Diseases: Autoimmune Responses to Tumor Antigens
2006, The Autoimmune Diseases, Fourth EditionParaneoplastic neuromuscular syndromes
1997, Neurologic ClinicsClinical presentation of small cell lung cancer
2012, Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC): Fourth EditionUpdate on paraneoplastic neurologic disorders
2010, Community OncologyNeuromuscular complications of cancer diagnosis and treatment
2005, Journal of Supportive Oncology
Copyright © 1995 Published by Elsevier B.V.